239 related articles for article (PubMed ID: 27754445)
1. L-Asparaginase Isolated from Phaseolus vulgaris Seeds Exhibited Potent Anti-Acute Lymphoblastic Leukemia Effects In-Vitro and Low Immunogenic Properties In-Vivo.
Mohamed SA; Elshal MF; Kumosani TA; Aldahlawi AM; Basbrain TA; Alshehri FA; Choudhry H
Int J Environ Res Public Health; 2016 Oct; 13(10):. PubMed ID: 27754445
[No Abstract] [Full Text] [Related]
2. Dynamic changes in specific anti-L-asparaginase antibodies generation during acute lymphoblastic leukemia treatment.
Walenciak J; Wyka K; Janczar S; Młynarski W; Zalewska-Szewczyk B
Pharmacol Rep; 2019 Apr; 71(2):311-318. PubMed ID: 30826572
[TBL] [Abstract][Full Text] [Related]
3. Monitoring of anti-L-asparaginase antibody and L-asparaginase activity levels in a pediatric patient with acute lymphoblastic leukemia and hypersensitivity to native Escherichia coli L-asparaginase during desensitization courses.
Kawahara Y; Morimoto A; Hayase T; Kashii Y; Fukuda T; Momoi MY
J Pediatr Hematol Oncol; 2014 Mar; 36(2):e91-3. PubMed ID: 23689289
[TBL] [Abstract][Full Text] [Related]
4. Comparative immunogenicity and structural analysis of epitopes of different bacterial L-asparaginases.
Pokrovsky VS; Kazanov MD; Dyakov IN; Pokrovskaya MV; Aleksandrova SS
BMC Cancer; 2016 Feb; 16():89. PubMed ID: 26867931
[TBL] [Abstract][Full Text] [Related]
5. Mutations in subunit interface and B-cell epitopes improve antileukemic activities of Escherichia coli asparaginase-II: evaluation of immunogenicity in mice.
Mehta RK; Verma S; Pati R; Sengupta M; Khatua B; Jena RK; Sethy S; Kar SK; Mandal C; Roehm KH; Sonawane A
J Biol Chem; 2014 Feb; 289(6):3555-70. PubMed ID: 24297177
[TBL] [Abstract][Full Text] [Related]
6. Curcumin potentiates antitumor activity of L-asparaginase via inhibition of the AKT signaling pathway in acute lymphoblastic leukemia.
Wang H; Geng QR; Wang L; Lu Y
Leuk Lymphoma; 2012 Jul; 53(7):1376-82. PubMed ID: 22185211
[TBL] [Abstract][Full Text] [Related]
7. Pharmacology, immunogenicity, and efficacy of a novel pegylated recombinant Erwinia chrysanthemi-derived L-asparaginase.
Chien WW; Allas S; Rachinel N; Sahakian P; Julien M; Le Beux C; Lacroix CE; Abribat T; Salles G
Invest New Drugs; 2014 Oct; 32(5):795-805. PubMed ID: 24829072
[TBL] [Abstract][Full Text] [Related]
8. [The role of anti L-asparaginase antibody in childhood acute lymphoblastic leukemia].
Akazai A; Oda M; Nishiuchi R; Horiuchi T; Henmi M; Manki A; Seino Y
Rinsho Ketsueki; 1996 Feb; 37(2):95-100. PubMed ID: 8852025
[TBL] [Abstract][Full Text] [Related]
9. Pharmacological and clinical monitoring in children with acute lymphoblastic leukemia treated with a biogeneric PEG-l-asparaginase product.
Matteo C; Colombini A; Bettini LR; Porcu L; Barzaghi S; Ceruti T; Silvestri D; Amoroso A; Dell'Acqua F; Gotti G; Nastasi C; Zucchetti M; Rizzari C
Pediatr Blood Cancer; 2022 Sep; 69(9):e29753. PubMed ID: 35561075
[TBL] [Abstract][Full Text] [Related]
10. PEG-asparaginase.
Fu CH; Sakamoto KM
Expert Opin Pharmacother; 2007 Aug; 8(12):1977-84. PubMed ID: 17696798
[TBL] [Abstract][Full Text] [Related]
11. Cloning and characterization of Halomonas elongata L-asparaginase, a promising chemotherapeutic agent.
Ghasemi A; Asad S; Kabiri M; Dabirmanesh B
Appl Microbiol Biotechnol; 2017 Oct; 101(19):7227-7238. PubMed ID: 28801829
[TBL] [Abstract][Full Text] [Related]
12. Hypersensitivity or development of antibodies to asparaginase does not impact treatment outcome of childhood acute lymphoblastic leukemia.
Woo MH; Hak LJ; Storm MC; Sandlund JT; Ribeiro RC; Rivera GK; Rubnitz JE; Harrison PL; Wang B; Evans WE; Pui CH; Relling MV
J Clin Oncol; 2000 Apr; 18(7):1525-32. PubMed ID: 10735901
[TBL] [Abstract][Full Text] [Related]
13. Hypersensitivity reactions to asparaginase therapy in acute lymphoblastic leukemia: immunology and clinical consequences.
Burke MJ; Zalewska-Szewczyk B
Future Oncol; 2022 Mar; 18(10):1285-1299. PubMed ID: 35107320
[TBL] [Abstract][Full Text] [Related]
14. Intravenous pegylated asparaginase versus intramuscular native Escherichia coli L-asparaginase in newly diagnosed childhood acute lymphoblastic leukaemia (DFCI 05-001): a randomised, open-label phase 3 trial.
Place AE; Stevenson KE; Vrooman LM; Harris MH; Hunt SK; O'Brien JE; Supko JG; Asselin BL; Athale UH; Clavell LA; Cole PD; Kelly KM; Laverdiere C; Leclerc JM; Michon B; Schorin MA; Welch JJ; Lipshultz SE; Kutok JL; Blonquist TM; Neuberg DS; Sallan SE; Silverman LB
Lancet Oncol; 2015 Dec; 16(16):1677-90. PubMed ID: 26549586
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of immunologic crossreaction of antiasparaginase antibodies in acute lymphoblastic leukemia (ALL) and lymphoma patients.
Wang B; Relling MV; Storm MC; Woo MH; Ribeiro R; Pui CH; Hak LJ
Leukemia; 2003 Aug; 17(8):1583-8. PubMed ID: 12886246
[TBL] [Abstract][Full Text] [Related]
16. Interaction between Gallic acid and Asparaginase to potentiate anti-proliferative effect on lymphoblastic leukemia cell line.
Sourani Z; Shirzad H; Shirzad M; Pourgheysari B
Biomed Pharmacother; 2017 Dec; 96():1045-1054. PubMed ID: 29217160
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetic/pharmacodynamic relationships of asparaginase formulations: the past, the present and recommendations for the future.
Avramis VI; Panosyan EH
Clin Pharmacokinet; 2005; 44(4):367-93. PubMed ID: 15828851
[TBL] [Abstract][Full Text] [Related]
18. Optimizing asparaginase therapy for acute lymphoblastic leukemia.
Rizzari C; Conter V; Starý J; Colombini A; Moericke A; Schrappe M
Curr Opin Oncol; 2013 Mar; 25 Suppl 1():S1-9. PubMed ID: 23380829
[TBL] [Abstract][Full Text] [Related]
19. [Comparison of the anti-leukemia effect and mechanism of L-asparaginase between two different strains].
Wang KM; Xu HG; Guo HX; Jin SW; Luo XQ; Fang JP
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Jun; 22(3):692-7. PubMed ID: 24989278
[TBL] [Abstract][Full Text] [Related]
20. [Update on L-asparaginase treatment in paediatrics].
Moscardó Guilleme C; Fernández Delgado R; Sevilla Navarro J; Astigarraga Aguirre I; Rives Solà S; Sánchez de Toledo Codina J; Fuster Soler JL; Parra Ramirez L; Molina Garicaño J; González Martínez B; Madero López L
An Pediatr (Barc); 2013 Nov; 79(5):329.e1-329.e11. PubMed ID: 23727426
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]